ORIGINAL RESEARCH article
Front. Cardiovasc. Med.
Sec. Heart Failure and Transplantation
This article is part of the Research TopicAdvancement in Personalized Cardiovascular Treatment for Heart FailureView all 3 articles
Initial High-Dose β-blockers Toleration with Reduced Ejection Fraction Heart Failure of Hospitalized Hypertensive Patients
Provisionally accepted
- West China Hospital, Sichuan University, Chengdu, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: β-blockers (BB) are the cornerstone of treatment for heart failure with reduced ejection fraction (HFrEF). However, due to potential adverse effects, guidelines recommend starting with a low dose and gradually titrating upwards. Hypertensive patients with HFrEF tend to have better drug responsiveness and prognosis, but it remains unclear whether they can tolerate initial high-dose BB. Therefore, this study aims to assess the tolerance of this population to initial high-dose BB therapy. Methods: A retrospective observational study included 307 hypertensive patients with HFrEF who initiated BB therapy and were admitted to the cardiology department at West China Hospital, Sichuan University. Patients' demographic and clinical information was collected through the electronic medical record (EMR) system. Patients were categorized into a high-dose group if their initial BB dose exceeded 1/8 of the target dose, all other patients were assigned to the standard-dose group. Multivariate logistic forward regression analysis was performed to explore factors influencing the prescriptions of intial high-dose BB and adverse safety outcomes related to BB therapy during hospitalization, including bradycardia, hypotension, acute HF, wheezing requiring bronchodilator therapy, and BB dose reduction or cessation. Results: Seventy patients (22.8%) were initially prescribed high-dose BB. Logistic forward regression analysis revealed that only coronary heart disease was negatively associated with the prescriptions of initial high-dose BB, with an odds ratio of 0.435 (95% CI: 0.247-0.763, P=0.004). Further logistic regression analysis demonstrated no independent association between the initial high-dose BB therapy and the occurrence of adverse safety outcomes, including bradycardia, hypotension, acute HF, wheezing requiring bronchodilator therapy, or BB dose reduction or discontinuation (all p < 0.05). Conclusion: Prescriptions of initial high-dose BB in hypertensive patients with HFrEF were not associated with an increased incidence of adverse safety outcomes. These findings indicate that initial high-dose BB therapy could be a viable strategy for this population.
Keywords: Heart failure with reduced ejection fraction, Hypertension, Initial High-Dose Beta-blockers, toleration, treatment strategy
Received: 25 Jul 2025; Accepted: 27 Nov 2025.
Copyright: © 2025 Li, Yang, Zhou, Wang and Chen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Xiaoping Chen
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.